Back to top
more

Kodiak Sciences (KOD)

(Real Time Quote from BATS)

$7.15 USD

7.15
150,835

+0.50 (7.52%)

Updated Aug 4, 2025 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

by Zacks Equity Research

KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.

Zacks Equity Research

Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)

by Zacks Equity Research

Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

by Zacks Equity Research

KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks Equity Research

KOD Completes Enrollment in Phase III Study for Eye Disease Candidate

by Zacks Equity Research

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Zacks Equity Research

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

by Zacks Equity Research

Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

Ahan Chakraborty headshot

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

by Ahan Chakraborty

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Zacks Equity Research

KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential

by Zacks Equity Research

Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

by Zacks Equity Research

KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks Equity Research

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks

by Zacks Equity Research

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.

Zacks Equity Research

Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks Equity Research

All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy

by Zacks Equity Research

Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?

by Zacks Equity Research

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

Zacks Equity Research

Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.

Zacks Equity Research

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

by Zacks Equity Research

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

Zacks Equity Research

Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Equity Research

Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B

by Zacks Equity Research

Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.

Zacks Equity Research

Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates

by Zacks Equity Research

Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.

Zacks Equity Research

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Zacks Equity Research

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

by Zacks Equity Research

Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.

Zacks Equity Research

Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.